BioStock: SynAct Pharma strengthens strategy and financials in Q2
RefinitivBacaan kurang dari 1 minit
SynAct Pharma has published its Q2 report, highlighting a sharpened development strategy for its lead compound, resomelagon, alongside an improved financial position. The company also highlighted the two-year extension of US patent protection for its resomelagon combination therapy. To gain further insights, BioStock reached out to CEO Jeppe Øvlesen for a comment.
Read the full interview at biostock.se:
https://biostock.se/en/2025/08/synact-pharma-strengthens-strategy-and-financials-in-q2/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini